Blog

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Jul 12 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (“CKD”) research program with NP-251 (“Repirinast”). In Q1 2022, the Company announced that it had initiated a new CKD research program to investigate Repirinast as part of…

Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

Jul 11 • 3 min read

-Cybin Inc. (NEO: CYBN | NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a Phase 1 N,N-dimethyltryptamine study from Entheon Biomedical Corp. (CSE: ENBI | OTCQB: ENTBF | FSE: 1XU1). This DMT study, which is the…

Season One of the Psychedelic Invest Podcast is Now Available on YouTube

Jul 11 • 2 min read

After ten informative episodes, season one of the Psychedelic Invest Podcast is wrapped and ready for the many future listeners that are exploring this exciting industry. Considering Psychedelic Invest’s mission to educate the masses to push this industry forward, we want to make all of our content as accessible as possible. This not only means…

Psychedelic Stock Market Update | June 2022

Jul 8 • 4 min read

In our psychedelic stock market update for May 2022, we asked a few simple, but important questions… Were we at a market bottom with the psychedelic stock sector ready to explode higher? Or, were the positive returns during the last few weeks of May just a market tease waiting to capitulate eager investors looking to…

Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder

Jul 8 • 3 min read

Clairvoyant Therapeutics, a Canadian biotech company, is pleased to announce it has initiated the first of 15 planned sites for CLARITY, the company’s Phase 2 clinical trial investigating psilocybin in the treatment of alcohol use disorder (AUD) (formerly called alcoholism). CLARITY is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560